Oxidative Stress in Patients with X-Linked Adrenoleukodystrophy

Cellular and Molecular Neurobiology

Volumn 36, Issue 4, 2016, Pages 497-512

  Deon, Marion ^a,b   Marchetti, Desirèe P ^a,b   Donida, Bruna ^a,b   Wajner, Moacir ^a,b   Vargas, Carmen ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Antioxidants; Oxidative damage biomarkers; Oxidative stress; X linked adrenoleukodystrophy

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; FREE RADICAL;

ADRENOLEUKODYSTROPHY; ALZHEIMER DISEASE; ASTROCYTE; CHEMOLUMINESCENCE; DISEASE COURSE; EPILEPSY; HUMAN; IN VITRO STUDY; LIPID PEROXIDATION; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; OXIDATIVE STRESS; PARKINSON DISEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; WHITE MATTER; BIOLOGICAL MODEL; METABOLISM; PATHOLOGY;

ADRENOLEUKODYSTROPHY; ANTIOXIDANTS; BIOMARKERS; FREE RADICALS; HUMANS; MODELS, BIOLOGICAL; OXIDATIVE STRESS;

EID: 84969557101     PISSN: 02724340     EISSN: 15736830     Source Type: Journal    
DOI: 10.1007/s10571-015-0234-2     Document Type: Review

References (81)

1. Aksenov M, Markesbery WR (2001) Changes in thiol content and expression of glutathione redox system genes in the hippocampus and cerebellum in Alzheimer’s disease. Neurosci Lett 302:141–145
2. Autrup H, Daneshvar B, Dragsted LO et al (1999) Biomarkers for exposure to ambient air pollution–comparison of carcinogen-DNA adduct levels with other exposure markers and markers for oxidative stress. Environ Health Perspect 107(3):233–238
3. Ayala A, Muñoz MF, Argüelles S (2014) Lipid peroxidation: production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. Oxid Med Cell Longev 2014:360438. doi:10.1155/2014/360438
4. Barschak AG, Sitta A, Deon M et al (2006) Evidence that oxidative stress is increased in plasma from patients with maple syrup urine disease. Metab Brain Dis 21:279–286
5. Berger J, Gärtner J (2006) X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetics aspects. Biochim Biophys Acta 1763:1721–1732
6. Berger J, Pujol A, Aubourg P, Forss-Petter S (2010) Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy. Brain Pathol 20:845–856
7. Berger J, Forss-Petter S, Eichler FS (2014) Pathophysiology of X-linked adrenoleukodystrophy. Biochimie 98:135–142
8. Bezman L, Moser AB, Raymond GV et al (2001) Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 49:512–517
9. Boyd-Kimball D, Castegna A, Sultana R et al (2005) Proteomic identification of proteins oxidized by Abeta (1–42) in synaptosomes: implications for Alzheimer’s disease. Brain Res 1044:206–215
10. Braverman NE, Moser AB (2012) Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta 1822(9):1442–1452
11. Brose RD, Avramopoulos D, Smith KD (2012) SOD2 as a potential modifier of X-linked adrenoleukodystrophy clinical phenotypes. J Neurol 259:1440–1447
12. Cai H, Harrison DG (2000) Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87:840–844
13. Davies KJ (2000) Oxidative stress, antioxidant defenses, and damage removal, repair and replacement systems. IUBMB Life 50(4–5):279–289
14. Deon M, Wajner M, Sirtori LR et al (2006) The effect of Lorenzo’s oil on oxidative stress in X-linked adrenoleukodistrophy. J Neurol Sci 247:157–164
15. Deon M, Sitta A, Barschak AG et al (2007) Introduction of lipid peroxidation and decrease of antioxidant defenses in symptomatic and asymptomatic patients with X-linked adrenoleukodystrophy. Int J Dev Neurosci 25:441–444
16. Deon M, Sitta A, Barschak AG et al (2008) Oxidative stress is induced in female carriers of X-linked adrenoleukodystrophy. J Neurol Sci 266:79–83
17. Di Biase A, Salvati S, Varí R et al (2000) Susceptibility to oxidation of plasma low-density lipoprotein in X-linked adrenoleukodystrophy: effects of simvastatin treatment. Mol Genet Metab 71(4):651–655
18. Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H (2002) Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med 32(11):1102–1115
19. Engelen M, Kemp S, de Visser M et al (2012) X-linked adrenoleukodystrophy (X-ALD): clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis 7:51
20. Fang YZ, Yang S, Wu G (2002) Free radicals, antioxidants, and nutrition. Nutrition 18(10):872–879
21. Fourcade S, López-Erauskin J, Galino J et al (2008) Early oxidative damage underlying neurodegenaration in X-adrenoleukodystrophy. Hum Mol Genet 17:1762–1773
22. Fourcade S, Ruiz M, Guilera C et al (2010) Valproic acid induces antioxidant effects in X-linked adrenoleukodystrophy. Hum Mol Genet 19:2005–2014
23. Fourcade S, López-Erauskin J, Ruiz M et al (2014) Mitochondrial dysfunction and oxidative damage cooperatively fuel axonal degeneration in X-linked adrenoleukodystrophy. Biochimie 98:143–149
24. Fridovich I (1999) Fundamental aspects of reactive oxygen species, or what’s the matter with oxygen. Ann N Y Acad Sci 893:13–18
25. Galea E, Launay N, Portero-Otin M et al (2012) Oxidative stress underlying axonal degeneration in adrenoleukodystrophy: a paradigm for multifactorial neurodegenerative diseases? Biochim Biophys Acta 1822:1475–1488
26. Gilg GA, Singh AK, Singh I (2000) Inducible nitric oxide synthase in the central nervous system of patients with X-adrenoleukodystrophy. J Neuropathol Exp Neurol 59(12):1063–1069
27. Gorgas K, Teigler A, Komljenovic D, Just WW (2006) The ether lipid-deficient mouse: tracking down plasmalogen functions. Biochim Biophys Acta 1763(12):1511–1526
28. Halliwell B (1994) Free radicals, antioxidants, and human disease: curiosity, cause or consequence? Lancet 344:721–724
29. Halliwell B (2006) Oxidative stress and neurodegeneration: where are we now? J Neurochem 97:1634–1658
30. Halliwell B, Gutteridge JMC (2007) Free radicals in biology and medicine. Oxford University Press, Oxford
31. Kampa M, Nistikaki A, Tsaousis V, Maliaraki N, Notas G, Castanas E (2002) A new automated method for the determination of the total antioxidant capacity (TAC) of human plasma, based on the crocin bleaching assay. BMC Clin Pathol 2(1):1–16
32. Kemp S, Wanders RJA (2010) Biochemical aspects of X-linked adrenoleukodystrophy. Brain Pathol 20(4):831–837
33. Kemp S, Berger J, Aubourg P (2012) X-linked adrenoleukodystrophy: clinical, metabolic, genetic andpathophysiological aspects. Biochim Biophys Acta 1822:1465–1474
34. Khan M, Pahan K, Singh AK, Singh I (1998) Cytokine-induced accumulation of very long-chain fatty acids in rat C6 glial cells: implication for X-adrenoleukodystrophy. J Neurochem 71(1):78–87
35. Khan M, Singh J, Singh I (2008) Plasmalogen deficiency in cerebral adrenoleukodystrophy and its modulation by lovastatin. J Neurochem 106(4):1766–1779
36. Kühn H, Borchert A (2002) Regulation of enzymatic lipid peroxidation: the interplay of peroxidizing and peroxide reducing enzymes. Free Radic Biol Med 33(2):154–172
37. Latorre E, Collado MP, Fernández I, Aragonés MD, Catalán RE (2003) Signaling events mediating activation of brain ethanolamine plasmalogen hydrolysis by ceramide. Eur J Biochem 270(1):36–46
38. Lee H-C, Wei Y-H (2005) Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int J Biochem Cell Biol 37:822–834
39. Levine RL, Stadtman ER (2001) Oxidative modification of proteins during aging. Exp Gerontol 36(9):1495–1502
40. Levine RL, Garland D, Oliver CN et al (1990) Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186:464–478
41. Lissi E, Salim-Hanna M, Pascual C, Del Castillo MD (1995) Evaluation of total antioxidant potential (TRAP) and total antioxidant reactivity from luminol-enhanced chemiluminescence measurements. Free Rad Biol Med 18:153–158
42. López-Erauskin J, Fourcade S, Galino J et al (2011) Antioxidants halt axonal neurodegeneration in a mouse model of X-adrenoleukopystrophy. Ann Neurol 70:84–92
43. López-Erauskin J, Galino J, Bianchi P, Fourcade S et al (2012) Oxidative stress modulates mitochondrial failure and cyclophilin D function in X-linked adrenoleukodystrophy. Brain 135(Pt12):3584–3598
44. López-Erauskin J, Galino J, Ruiz M et al (2013) Impaired mitochondrial oxidative phosphorylation in the peroxisomal disease X-linked adrenoleukodystrophy. Hum Mol Genet 22(16):3296–3305
45. Maier EM, Kammerer S, Muntau AC, Wichers M, Braun A, Roscher AA (2002) Symptoms in carriers of Adrenoleukodystrophy relate to skewed X inactivation. Ann Neurol 52(5):683–688
46. Miller DM, Buettner GR, Aust SD (1990) Transition metals as catalysts of “autoxidation” reactions. Free Radic Biol Med 8(1):95–108
47. Moser HW (2006) Therapy of X-linked adrenoleukodystrophy. NeuroRx 3:246–253
48. Moser HW, Moser AB (1991) Measurement of saturated very long chain fatty acid in plasma. In: Hommes FA (ed) Techniques in diagnostics human biochemical genetics. Wiley-Liss, New York, pp 177–191
49. Moser AB, Kreiter N, Bezman L et al (1999) Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 45(1):100–110
50. Moser H, Smith KD, Watkins PA, Powers J, Moser AB (2001) X-linked adrenoleukodystrophy. In: Scriver CR, Sly WS (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New-York, pp 3257–3301
51. Moser HW, Raymond GV, Dubey P (2005a) Adrenoleukodystrophy- new approaches to a neurodegenerative disease. JAMA 294:3131–3134
52. Moser HW, Raymond GV, Lu SE et al (2005b) Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil. Arch Neurol 62(7):1073–1080
53. Negretto GW, Deon M, Burin M et al (2014) In vitro effect of genistein on DNA damage in leukocytes from mucopolysaccharidosis IVA patients. Mol Genet Metab 111(2):205–208
54. Niki E, Yoshida Y, Saito Y, Noguchi N (2005) Lipid peroxidation: mechanisms, inhibition, and biological effects. BBRC 338(1):668–676
55. Norton WT (1984) Some thoughts on the neurobiology of the leukodystrophies. Neuropediatrics 15:28–31
56. Ohyashiki T, Sakata N, Matsui K (1994) Changes in SH reactivity of the protein in porcine intestinal brush-border membranes associated with lipid peroxidation. J Biochem 115:224–229
57. Pai GS, Khan M, Barbosa E et al (2000) Lovastatin therapy for X-linked adrenoleukodystrophy: clinical and biochemical observations on 12 patients. Mol Genet Metab 69:312–322
58. Peters C, Charnas LR, Tan Y et al (2004) Cerebral X-linked adrenoleukodystrophy: the international hematopoietic cell transplantation experience from 1982 to 1999. Blood 104(3):881–888
59. Petrillo S, Piemonte F, Pastore A et al (2013) Glutathione imbalance in patients with X-linked adrenoleukodystrophy. Mol Genet Metab 109:366–370
60. Powers JM, Pei Z, Heinzer AK et al (2005) Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol 64:1067–1079
61. Radi R, Beckman JS, Bush KM, Freeman BA (1991) Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch Biochem Biophys 288(2):481–487
62. Ribas GS, Manfredini V, De Mari J et al (2010) Reduction of lipid and protein damage in patients with disorders of propionate metabolism under treatment: a possible protective role of L-carnitine supplementation. Int J Dev Neurosci 28(2):127–132
63. Rockenbach FJ, Deon M, Marchese DP et al (2012) The effect of bone marrow transplantation on oxidative stress in X-linked adrenoleukodystrophy. Mol Genet Metab 106:231–236
64. Schofield D, Braganza JM (1996) Shortcomings of an automated assay for total antioxidant status in biological fluids. Clin Chem 42(10):1712–1714
65. Seifried HE, Anderson DE, Fisher EI, Milner JA (2007) A review of the interaction among dietary antioxidants and reactive oxygen species. J Nutr Biochem 18:567–579
66. Shichiri M (2014) The role of lipid peroxidation in neurological disorders. J Clin Biochem Nutr 54(3):151–160
67. Singh I, Pujol A (2010) Pathomecanisms underlying X-adrenoleukodystrophy: a three-hit hypothesis. Brain Pathol 20:838–844
68. Singh I, Pahan K, Khan M (1998) Lovastatin and sodium phenylacetate normalize the levels of very long chain fatty acids in skin fibroblasts of X-adrenoleukodystrophy. FEBS Lett 426:342–346
69. Sirtori LR, Dutra-Filho CS, Fitarelli D et al (2005) Oxidative stress in patients with phenylketonuria. Biochim Biophys Acta 1740:68–73
70. Smith KD, Kemp S, Braiterman LT et al (1999) X-linked adrenoleukodystrophy: genes, mutations, and phenotypes. Neurochem Res 24(4):521–535
71. Stadtman ER, Levine RL (2003) Free-radical mediated oxidation of free amino acids and amino acid residues in proteins. Amino Acids 25:207–218
72. Tarpey MM, Fridovich I (2001) Methods of detection of vascular reactive species: nitric oxide, superoxide, hydrogen peroxide, and peroxynitrite. Circ Res 89(3):224–236
73. Tolar J, Orchard PJ, Bjoraker KJ, Ziegler RS, Shapiro EG, Charnas L (2007) N-acetyl-l-cysteine improves outcome of advanced cerebral adrenoleukodystrophy. Bone Marrow Transplant 39(4):211–215
74. Triantafyllou P, Economou M, Vlachaki E et al (2014) Multiple endocrine disorders associated with adrenomyeloneuropathy and a novel mutation of the ABCD1 gene. Pediatr Neurol 50(6):622–624
75. Uto T, Contreras MA, Gilg AG, Singh I (2008) Oxidative imbalance in nonstimulated X-adrenoleukodystrophy-derived lymphoblasts. Dev Neurosci 30:410–418
76. Valko M, Leibfritz D, Moncola J, Cronin M, Mazura M, Telser I (2007) Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol 39(1):44–84
77. Vargas CR, Wajner M, Sirtori LR et al (2004) Evidence that oxidative stress is increased in patients with X-linked adrenoleukodystrophy. Biochim Biophys Acta 1688:26–32
78. Wajner M, Latini A, Wyse AT, Dutra-Filho CS (2004) The role of oxidative damage in the neuropathology of organic acidurias: insights from animal studies. J Inherit Metab Dis 27:427–448
79. Wanders RJ, Waterham HR (2006) Peroxisomal disorders: the single peroxisomal enzyme deficiencies. Biochim Biophys Acta 1763(12):1707–1720
80. Wanders RJA, Schutgens RBH, Barth PG, Tager JM, Van Den Bosch H (1993) Postnatal diagnosis of peroxisomal disorders: a biochemical approach. Biochemie 75:269–279
81. Zheng M, Storz G (2000) Redox sensing by prokaryotic transcription factors. Biochem Pharmacol 59(1):1–6